| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Citi |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2009-01-14 11:19:50 |
| Versijas komentārs | |
| Teksts |
JSC Grindeks confirms published statement at The Baltic Course (14.01.2009.) of the Chairman of the Council Kirovs Lipmans, that Business plan of the Company anticipates 185 million Lats turnover for 2013. Also Grindeks notifies, that fulfillment of the Business plan is closely linked with overall economical situation in Grindeks target markets – Russia and other CIS countries, as well as entrance new markets. About Grindeks JSC Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development and manufacturing of brand products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of Grindeks’s products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, USA. Grindeks shares are listed in the Official List of Riga Stock Exchange. Contacts: Laila Kļaviņa Head of the Communications Department JSC Grindeks Phones: +371 67083370, + 371 29256012 e-mail: laila.klavina@grindeks.lv |
| Pielikumi |
|